{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:48:48Z","timestamp":1784731728884,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003532"],"award-info":[{"award-number":["82003532"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007289","name":"Nanjing Medical University","doi-asserted-by":"publisher","award":["NMUB2019154"],"award-info":[{"award-number":["NMUB2019154"]}],"id":[{"id":"10.13039\/501100007289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Urology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ajur.2025.05.001","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T02:55:18Z","timestamp":1749696918000},"page":"154-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development and validation of prostate-specific membrane antigen\u2013adjusted Prostate Imaging Reporting and Data System: A new approach to enhancing the accuracy of diagnosing treatment-na\u00efve primary prostate cancer"],"prefix":"10.1016","volume":"13","author":[{"given":"Xiaoyuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9036-8275","authenticated-orcid":false,"given":"Jieping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rushuai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8387-7806","authenticated-orcid":false,"given":"Hongwei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyue","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8714-3084","authenticated-orcid":false,"given":"Kuangyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Afshar-Oromieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longjiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Cahid","family":"Civelek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1089-3095","authenticated-orcid":false,"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajur.2025.05.001_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ajur.2025.05.001_bib2","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ajur.2025.05.001_bib3","first-page":"241","article-title":"Prostate-specific membrane antigen as a target for cancer imaging and therapy","volume":"59","author":"Kiess","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ajur.2025.05.001_bib4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1053\/j.semnuclmed.2016.04.004","article-title":"Current status of prostate-specific membrane antigen targeting in nuclear medicine: clinical translation of chelator containing prostate-specific membrane antigen ligands into diagnostics and therapy for prostate cancer","volume":"46","author":"Kratochwil","year":"2016","journal-title":"Semin Nucl Med"},{"issue":"Suppl. 2","key":"10.1016\/j.ajur.2025.05.001_bib5","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.2967\/jnumed.116.186767","article-title":"Prostate-specific membrane antigen ligands for imaging and therapy","volume":"58","author":"Eiber","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ajur.2025.05.001_bib6","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1148\/rg.2017170035","article-title":"Clinical PET imaging in prostate cancer","volume":"37","author":"Wallitt","year":"2017","journal-title":"Radiographics"},{"key":"10.1016\/j.ajur.2025.05.001_bib7","first-page":"67","article-title":"PSMA uptake on 68Ga-PSMA-11-PET\/CT positively correlates with prostate cancer aggressiveness","volume":"66","author":"Chen","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ajur.2025.05.001_bib8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","article-title":"PET imaging with a 68Ga-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions","volume":"40","author":"Afshar-Oromieh","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ajur.2025.05.001_bib9","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2025.05.001_bib10","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2967\/jnumed.116.184457","article-title":"Detection efficacy of hybrid 68Ga-PSMA ligand PET\/CT in prostate cancer patients with biochemical recurrence after primary radiation therapy defined by Phoenix criteria","volume":"58","author":"Einspieler","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ajur.2025.05.001_bib11","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2967\/jnumed.117.191031","article-title":"PSMA ligands for PET imaging of prostate cancer","volume":"58","author":"Schwarzenboeck","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ajur.2025.05.001_bib12","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s00259-017-3887-x","article-title":"Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET\/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy","volume":"45","author":"Seitz","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ajur.2025.05.001_bib13","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy","volume":"57","author":"Baum","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ajur.2025.05.001_bib14","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1007\/s00259-021-05217-2","article-title":"Can 68Ga-PSMA-11 PET\/CT predict pathological upgrading of prostate cancer from MRI-targeted biopsy to radical prostatectomy?","volume":"48","author":"Yin","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ajur.2025.05.001_bib15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","article-title":"Simultaneous 68Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer","volume":"70","author":"Eiber","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2025.05.001_bib16","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1148\/radiol.2018181981","article-title":"68Ga-PSMA-11 PET: better at detecting prostate cancer than multiparametric MRI?","volume":"289","author":"Civelek","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.ajur.2025.05.001_bib17","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233023","article-title":"PSMA PET parameters for predicting outcomes in patients with prostate cancer","volume":"309","author":"Civelek","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.ajur.2025.05.001_bib18","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ejrad.2013.01.008","article-title":"Standardized uptake values for [18F] FDG in normal organ tissues: comparison of whole-body PET\/CT and PET\/MRI","volume":"82","author":"Heusch","year":"2013","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ajur.2025.05.001_bib19","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ajur.2025.05.001_bib20","first-page":"1644","article-title":"The PRIMARY score: using intra-prostatic PSMA PET\/CT patterns to optimise prostate cancer diagnosis","volume":"63","author":"Emmett","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ajur.2025.05.001_bib21","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate Imaging Reporting and Data System version 2.1: 2019 update of Prostate Imaging Reporting and Data System version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2025.05.001_bib22","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2967\/jnumed.117.195255","article-title":"Proposal for a structured reporting system for prostate-specific membrane antigen-targeted PET imaging: PSMA-RADS version 1.0","volume":"59","author":"Rowe","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ajur.2025.05.001_bib23","doi-asserted-by":"crossref","first-page":"787.e17","DOI":"10.1016\/j.urolonc.2021.04.024","article-title":"Clinical value of 18F-FDG PET\/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer","volume":"39","author":"Civelek","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ajur.2025.05.001_bib24","doi-asserted-by":"crossref","first-page":"382","DOI":"10.21037\/tau.2020.03.06","article-title":"Comparison of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography\/computed tomography (PET\/CT) and multi-parametric magnetic resonance imaging (MRI) in the evaluation of tumor extension of primary prostate cancer","volume":"9","author":"Chen","year":"2020","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.ajur.2025.05.001_bib25","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2967\/jnumed.118.221010","article-title":"Combination of 68Ga-PSMA PET\/CT and multiparametric MRI improves the detection of clinically significant prostate cancer: a lesion-by-lesion analysis","volume":"60","author":"Chen","year":"2019","journal-title":"J Nucl Med"},{"issue":"Suppl. 1","key":"10.1016\/j.ajur.2025.05.001_bib26","first-page":"455","article-title":"PET-MRI derived 18F-FDG liver SUV metrics: effects of hepatic steatosis and comparison with PET-CT","volume":"58","author":"Civelek","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ajur.2025.05.001_bib27","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/MNM.0000000000000566","article-title":"Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET\/CT imaging","volume":"37","author":"Demirci","year":"2016","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.ajur.2025.05.001_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40644-019-0211-y","article-title":"Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution","volume":"19","author":"Ferreira","year":"2019","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.ajur.2025.05.001_bib29","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajur.2025.05.001_bib30","first-page":"245","article-title":"Prostate cancer\u2014major changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Buyyounouski","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ajur.2025.05.001_bib31","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ajur.2025.05.001_bib32","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1002\/cam4.5516","article-title":"Ability of 68Ga-PSMA PET\/CT SUVmax to differentiate ISUP GG2 from GG3 in intermediate-risk prostate cancer: a single-center retrospective study of 147 patients","volume":"12","author":"Yi","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.ajur.2025.05.001_bib33","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00259-020-04863-2","article-title":"68Ga-PSMA PET\/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study","volume":"48","author":"Zhang","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ajur.2025.05.001_bib34","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1007\/s00259-021-05261-y","article-title":"Diagnostic performance of 68Ga-PSMA-11 PET\/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study","volume":"48","author":"Ferraro","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ajur.2025.05.001_bib35","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s00345-020-03490-8","article-title":"Detection of prostate cancer with 18F-DCFPyL PET\/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial","volume":"39","author":"Bodar","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.ajur.2025.05.001_bib36","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1148\/radiol.2019190687","article-title":"Diagnostic accuracy of multiparametric MRI versus 68Ga-PSMA-11 PET\/MRI for extracapsular extension and seminal vesicle invasion in patients with prostate cancer","volume":"293","author":"Muehlematter","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.ajur.2025.05.001_bib37","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/02841850902889846","article-title":"Accuracy of 3-Tesla magnetic resonance imaging for the staging of prostate cancer in comparison to the Partin tables","volume":"50","author":"Augustin","year":"2019","journal-title":"Acta Radiol"}],"container-title":["Asian Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214388225000657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214388225000657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T20:41:47Z","timestamp":1780260107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214388225000657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2214388225000657"],"URL":"https:\/\/doi.org\/10.1016\/j.ajur.2025.05.001","relation":{},"ISSN":["2214-3882"],"issn-type":[{"value":"2214-3882","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of prostate-specific membrane antigen\u2013adjusted Prostate Imaging Reporting and Data System: A new approach to enhancing the accuracy of diagnosing treatment-na\u00efve primary prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajur.2025.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Editorial Office of Asian Journal of Urology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}